Three-quarters of American voters support continued funding for Pepfar, the global HIV and AIDS relief program, even as the Trump administration moves to slash the initiative and redirect its resources, according to new polling that reveals a stark gap between public sentiment and current policy direction.
The survey found that 74 percent of likely midterm voters back the program, with even stronger support for the moral case behind it. Four in five respondents said there is a compelling ethical argument for funding lifesaving HIV treatment globally, regardless of personal circumstances. When voters learned more details about Pepfar's work, support climbed further.
"It's going to be seen positively if Republicans or Democrats pursue Pepfar," said Jennifer Kates, senior vice president and director of global and public health policy at KFF. The polling aligns with other surveys showing the program enjoys broad bipartisan backing, a legacy that stretches back to its creation under President George W. Bush in 2003.
Yet the administration is moving aggressively to reshape the program. In May, the State Department announced it would keep nearly all Pepfar funding rather than splitting it with the CDC, which would receive only $150 million instead of a potential $2 billion. The restructuring follows the dissolution of USAID last year and its absorption into the State Department.
Domestically, the administration's proposed budget includes a $1.6 billion cut to HIV prevention funding. The changes represent a fundamental shift away from the partnership model that has defined the program for two decades.
"USAID is already gone," said Asia Russell, executive director of Health Gap, an HIV advocacy group. "Now they want to cut off the West Wing too." The new approach relies on bilateral country agreements that include HIV work but don't prioritize it, raising concerns about the ability to track spending and maintain the surveillance infrastructure Pepfar has built.
The polling data suggests the administration may face political blowback. Michael Vazquez, founder of the firm that conducted the survey, noted a disconnect between policymakers and voters. "Voters do not want to feel that their vote and their tax dollars are being directed away from things that make them proud to be an American," he said.
Economists and pollsters point out that framing global health as an investment in American values and business interests could boost political support. Economic anxiety typically dominates voting calculations, but positioning Pepfar as both moral and economically beneficial appears to strengthen its standing.
The timing of the cuts raises immediate concerns beyond domestic politics. Pepfar's network of labs, expertise, and surveillance systems has become central to pandemic detection globally. An Ebola outbreak in Africa went undetected for weeks after significant funding lapses from the U.S., demonstrating what happens when that capacity weakens.
"Pepfar built a platform for global pandemic detection and response," Russell said. "The state department is attempting to dissolve that in the midst of an uncontrolled, large, deadly outbreak." Congress could reverse course by mandating continued CDC collaboration, but no such effort has gained traction.
The progress made against HIV over the past two decades is fragile. Kates warned that lifting pressure now could trigger new surges in cases, and once infections spike, detecting the problem often comes too late. Momentum matters in global disease control, and policy whiplash can undo years of work.
Author James Rodriguez: "The gap between what voters want and what's happening on the Hill is stunning, and it won't stay invisible come November."
Comments